Shots:

• The label update includes dosing flexibility of Cosentyx up to 300 mg based on clinical response & SC structural data of 24 wks.- showing inhibition in progression of joint damage in PsA
• Cosentyx label update is based on safety and efficacy of 300mg in follow-up titration & results from P-III FUTURE 5 study (N=996) @24 wks. showing results of no radiographic disease progression in 90% of patients
• Cosentyx is novel inhibitor for IL-17A in PsA & AS- prescribed to 160-000 patients WW. The updated label is applicable in EU including all EEA countries

to read full press release/ article

Ref: Novartis | Image: Novartis